Media Articles Related to Aricept (Donepezil)
ARICEPT (Donepezil) effective for severe Alzheimer's disease
Source: The Doctors Lounge - Neurology
Donepezil reverses some aspects of cognitive deterioration seen in severe Alzheimer's disease.
Anavex agreement with The Roskamp Institute to advance the clinical development of ANAVEX PLUS
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.01.15]
Anavex Life Sciences Corp. has announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (Aricept®) for the treatment of Alzheimer's disease.
Sleep disruption in Alzheimer's disease
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2014.02.28]
Being awake at night and dozing during the day can be a distressing early symptom of Alzheimer's disease, but how the disease disrupts our biological clocks to cause these symptoms has remained elusive.Now, scientists from Cambridge have discovered that in fruit flies with Alzheimer's the biological clock is still ticking but has become uncoupled from the sleep-wake cycle it usually regulates.
Earlier diagnosis of Alzheimer's disease through novel imaging technique
Source: MRI / PET / Ultrasound News From Medical News Today [2014.02.26]
New nuclear imaging techniques help in detecting Alzheimer's disease much earlier than before. Recently developed tracers, used with positron emission tomography (PET) make beta-amyloid in the brain visible. This part of a protein, which is a main causal factor of Alzheimer's, can now be detected long before the onset of the symptoms.
Targeting selected amyloid-beta dimers in early stages of Alzheimer's disease
Source: IT / Internet / E-mail News From Medical News Today [2014.02.21]
Researchers studying peptides using the Gordon supercomputer at the San Diego Supercomputer Center (SDSC) at the University of California, San Diego have found new ways to elucidate the creation of the toxic oligomers associated with Alzheimer's disease.
Published Studies Related to Aricept (Donepezil)
Donepezil and memantine for moderate-to-severe Alzheimer's disease. 
disease... CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued
Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. [2011.11]
OBJECTIVES: To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair... CONCLUSION: Participants randomized to donepezil had no significant improvement in delirium presence or severity but experienced more side effects. Overall, sufficient evidence was not found from this pilot study to warrant a definitive Phase III trial. (c) 2011, Copyright the Authors Journal compilation (c) 2011, The American Geriatrics Society.
Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. [2011.08]
Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimer's disease (AD)...
Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial. [2011.05]
BACKGROUND: Our aim was to assess the safety, tolerability, and efficacy signal of early donepezil administration with regard to enhancing recovery in a diverse acute ischemic stroke population... CONCLUSIONS: Adjuvant donepezil therapy initiated within 24 hours of acute ischemic stroke was safe and tolerated at 5 mg/day to 10 mg/day. The study met a priori criteria to move forward with a randomized clinical trial. Copyright (c) 2011 National Stroke Association. Published by Elsevier Inc. All rights reserved.
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. [2011.05]
CONCLUSIONS: In this exploratory study, SB-742457 and donepezil were associated with improvements in global function. Treatment effect on cognition for both SB-742457 and donepezil was smaller than those previously observed in previous clinical studies with donepezil. Copyright (c) 2010 John Wiley & Sons, Ltd.
Clinical Trials Related to Aricept (Donepezil)
Aricept to Improve Functional Tasks in Vascular Dementia [Recruiting]
Medications for memory improvement are available but they may not actually improve the
ability to do real world tasks. The purpose of this research study is to determine if a
medicine used to treat memory problems donepezil(Aricept) enhances the ability to remember
steps of functional tasks and the actual ability to perform tasks relevant to real-life
independence. Aricept is an FDA approved medication for the treatment of Alzheimer's
disease. Aricept is an investigational drug for the purposes of this study, and is not
approved for this purpose.
Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with
Dementia with Lewy Bodies (DLB).
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimerâs Disease [Completed]
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to
moderate Alzheimer’s disease (AD). Aricept has been shown to improve the memory and thinking
abilities, activities of daily living and global function in patients. The purpose of the
study is to further investigate the effectiveness and safety of donepezil in patients with
severe Alzheimer’s disease.
Donepezil is thought to work in the brain by increasing the levels of an important brain
chemical called acetylcholine. This chemical helps a person’s memory to work better.
Donepezil and Memantine in Moderate to Severe Alzheimer's Disease [Recruiting]
The trial will examine whether pharmacological treatment with donepezil, memantine or
combination of memantine and donepezil is any better than a placebo (dummy) treatment in
people with Alzheimer's disease who have reached the moderate to severe stage of illness.
Using a double blind design, where neither the investigators nor participants know who is
receiving which treatment, participants will be randomly assigned to one of these four
treatment groups (donepezil and memantine, memantine only, donepezil only or placebo). In
order to keep both the investigators and participants blind to drug allocation a double
dummy design will be necessary. This means that each participant will receive 2 treatments â
either an active form or placebo of each of the 2 study drugs.
1. Patients with Alzheimer's disease (AD) who continue donepezil beyond the point of
transition from moderate to severe dementia continue to show significantly less decline
on ratings of cognitive function and activities of daily living over the following 12
months than those discontinuing donepezil.
2. Patients with AD who change to memantine therapy in place of donepezil at the point of
transition from moderate to severe dementia show significantly smaller decline on
ratings of cognitive function and activities of daily living over the following 12
months than those who receive placebo.
3. Patients given the combination of memantine and donepezil at the point of transition
from moderate to severe dementia show significant additive or synergistic benefits on
measures of activities of daily living and cognitive function after 12 months compared
to those patients continuing on either drug as a single treatment.
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease [Recruiting]
The purpose of this study is to compare 23 mg donepezil sustained release to the currently
marketed formulation of 10 mg donepezil immediate release in patients with severe
Reports of Suspected Aricept (Donepezil) Side Effects
Electrocardiogram QT Prolonged (26),
Drug Interaction (24),
Altered State of Consciousness (21),
Loss of Consciousness (18), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 9 ratings/reviews, Aricept has an overall score of 4.67. The effectiveness score is 5.56 and the side effect score is 6.44. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Aricept review by care giver of 69 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Alzheimers|
|Dosage & duration:|| || 5g for one month rising to 10g (dosage frequency: daily) for the period of 3 months total - and on-going|
|Other conditions:|| || None|
|Other drugs taken:|| || None|
|Benefits:|| || Only moderate improvements noted on the 5g dosage.
Improvements much more noticeable at 10g - or after 30 days of taking medication. Less confusion, more awareness in social surroundings, more outward and positive in attitude. |
|Side effects:|| || So far no negative noted|
|Comments:|| || Take one pill in the morning.
Also vitamin supplements (Multi-vitamin, brain-booster vitamin, and homo-cysteine level reducer) |
Aricept review by care giver of 80 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || Alzheimer's disease|
|Dosage & duration:|| || 10 mg taken once daily for the period of 6 months|
|Other conditions:|| || hernia, teeth problems|
|Other drugs taken:|| || Tamasapan|
|Benefits:|| || We could not identify any benefits at all. The behavior and memory problems remained unchanged or worsened over time. Anxiety continued to increase and the dementia progressed systematically. Disorientation continued to increase and the patient became more and more difficult to manage. It appeared that irritability increased and the patient became more agitated more easily.|
|Side effects:|| || There was some indication that there was at least some increase nausa as well as some infrequent but increased bouts of diarrhea. There were a few episodes of vomiting, but it might be attributed to other factors for this one side effect. There was definitely increased insomnia as well as loss of appetite, but it can not be definitively stated that the drug alone contributed to these although it did occur after the drug was begun.|
|Comments:|| || The patient was given a daily dose. After transfer to a care facility, the regimentation in taking the dose was firmly set in place. Staff medical personnel on site did not observe any benefits, and as a result, after about 6 months the prescription was terminated. During the time the drug was used, there was a patient review every other week to ascertain whether there seemed to be any improvement in the patient. Memory tests were administered and one-on-one interviews were executed by medical personnel. The results of the memory testing showed no net improvement nor was there any identifiable changes that might be considered positive. Ultimately her psychiatrist in consultation with the family decided that the drug did not seem to provide any net gain.|
Aricept review by care giver of 67 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || short term memory loss|
|Dosage & duration:|| || 5 mg taken once for the period of once|
|Other conditions:|| || severe head pain, feel like throwing up|
|Other drugs taken:|| || welbutrin|
|Benefits:|| || none, only took one pill and found that the side effects do not warrant continued use.|
|Side effects:|| || severe head pain, feel like throwing up, felt lousy for 12 hours after taking first pill.|
|Comments:|| || Will not take pill again. The side effects of loosing a nights sleep, having severe head pain, and feeling like throwing up will result in not taking another pill as this drug does not agree with patient. |